Meeting to be held on December 12 hosted by Oppenheimer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Takeda, Keros Therapeutics enter exclusive elritercept license agreement
- Keros Therapeutics announces global license agreement with Takeda
- Keros Therapeutics Showcases Innovations at Major Conferences
- Keros Therapeutics Reports Q3 2024 Financial Results
- Keros Therapeutics reports Q3 EPS ($1.41), consensus ($1.28)
Questions or Comments about the article? Write to editor@tipranks.com